BPC-157 for Gut Health: Why Ulcerative Colitis Became the FDA Test Case

Most articles about BPC-157 treat it as a fitness peptide, a “wolverine compound” for tendons, ligaments, and joint pain. That framing skips the compound’s actual origin and the specific question regulators were asked to answer in 2026. BPC-157 was discovered in stomach research, its deepest animal evidence base is digestive, and when the FDA formally evaluated it this year, the agency evaluated ulcerative colitis, not sports recovery.

BPC-157 Started as Gastric Research, Not a Recovery Peptide

BPC-157 (“Body Protection Compound 157”) is a synthetic 15-amino-acid fragment derived from a larger protein isolated from human gastric juice. It was first characterized in the early 1990s by Predrag Sikirić and colleagues in Zagreb, Croatia, who were investigating a theory that the stomach actively coordinates the body’s response to injury and stress, a concept they called “organoprotection.” The 15-amino-acid fragment thought to carry that activity was isolated from a much larger, roughly 40,000-dalton gastric protein and named BPC-157.

That gastrointestinal starting point matters for everything that follows. Before BPC-157 was ever tested on a tendon, it was tested on stomach lining.

The Foundational Animal Research Was About Ulcers and Intestinal Injury

The bulk of the early BPC-157 literature is rodent research on the gut, not the musculoskeletal system. Researchers first tested it against chemically and stress-induced gastric ulcers, then extended the same molecule to models of intestinal damage: colitis induced by cysteamine or by chemical irritants, colon-colon and ileoileal anastomosis healing after bowel surgery, and intestinal fistulas. A 2024 review of BPC-157’s intestinal anastomosis research in rats describes healing effects across multiple types of gut surgery and injury models, building on earlier work showing BPC-157 could heal cysteamine-induced colitis alongside colon anastomoses and restore blood flow in a rat model of ischemic colitis.

This is a genuinely large body of preclinical evidence, but it is rodent data. It establishes biological plausibility for gut effects. It does not, by itself, establish that BPC-157 helps human digestive disease. That distinction is exactly what the FDA’s 2026 review had to grapple with.

Why the FDA’s 2026 Evaluation Focused Specifically on Ulcerative Colitis

In July 2026, the FDA’s Pharmacy Compounding Advisory Committee met to decide whether BPC-157 (free base) and BPC-157 (acetate) should be added to the 503A Bulks List (the list of substances state-licensed pharmacies are permitted to use to compound a drug for an individual patient). Being added to that list is not, and does not create, a new drug approval.

Four uses for BPC-157 were formally nominated for review: tendonitis, ulcerative colitis, Crohn’s disease, and celiac disease. The FDA declined to evaluate three of the four, writing that those nominations “did not include sufficient information” and that the agency “did not identify clinical studies using BPC-157 in these populations.” Ulcerative colitis was the only nominated use backed by an actual human trial, so it became the subject of the agency’s entire 68-page review.

Even that trial was thin. FDA reviewers identified one randomized, placebo-controlled study of roughly 46 participants who received BPC-157 as a rectal enema, not an injection, capsule, or nasal spray, for about two weeks. Because the results were reported only in a meeting abstract rather than a full peer-reviewed paper, basic details such as the primary endpoint, inclusion criteria, and statistical plan were not available to reviewers.

FDA staff reviewed this evidence and recommended against adding BPC-157 to the list, stating there was a “lack of evidence to support the effectiveness of BPC-157 (free base) and BPC-157 acetate as a treatment for ulcerative colitis.” Agency scientists also raised concerns that the substance itself is “not well-characterized,” meaning the agency could not fully establish quality standards for what is actually in a given batch.

The advisory committee did not follow that recommendation. After roughly four and a half hours of discussion, the committee voted 8-6-1, twice, once for the free-base form and once for the acetate form, to recommend BPC-157 for the 503A Bulks List anyway. Committee members who voted no cited the lack of randomized controlled trials and unresolved safety questions; members who voted yes generally argued that patients are already using unregulated versions of the peptide and that a licensed compounding pathway would be safer than the gray market. The vote is a nonbinding recommendation. The FDA can accept, modify, or reject it, and any change would still require formal notice-and-comment rulemaking, a process that extends into 2027 at the earliest.

Why Crohn’s Disease, Celiac Disease, and General “Gut Healing” Are Separate Claims

It is tempting to read “the FDA looked at BPC-157 for gut health” as support for the compound broadly. The 2026 review does the opposite: it draws a sharp line around ulcerative colitis specifically, and it is explicit that Crohn’s disease and celiac disease were not reviewed on their merits. They were not reviewed at all, because no one submitted clinical evidence for them. An indication that was never evaluated has less regulatory backing than one that was evaluated and still fell short, not more.

The same logic applies to informal “gut healing” claims built from the animal literature. A rat study on colon-colon anastomosis, a rat study on chemically induced colitis, and a small human ulcerative colitis enema trial are three different experiments answering three different questions. Combining them into a general claim that BPC-157 “heals the gut” glosses over which specific condition, dose, and route of administration each result actually applies to, which is the exact distinction the FDA’s condition-by-condition review was designed to enforce.

Emergency physician Owais Durrani made a related point to Healio after the vote: the practical risk is a mismatch between what was studied and what gets prescribed. BPC-157 was evaluated for ulcerative colitis, but, as he put it, “almost nobody is asking their doctor for these for ulcerative colitis.” Once a substance sits on the compounding list, clinicians can prescribe it off-label for anything, and the gap between the narrow question regulators actually answered and the broad claims used to market the peptide is where confusion tends to start.

Biological Plausibility vs. Demonstrated Clinical Benefit

These two things are not the same, and the BPC-157 file shows the gap clearly.

Biological plausibility means there is a coherent mechanism and supporting animal data suggesting an effect could occur. BPC-157 has that, especially for gut tissue. Demonstrated clinical benefit means adequately sized, controlled, peer-reviewed human trials have actually shown the effect, ideally replicated by more than one research group. BPC-157 does not have that yet, for any indication.

The route-of-administration problem makes this especially stark. Across every published human study the FDA could locate, roughly 80 people total have ever received BPC-157, by rectal enema, intra-articular injection (combined with a second peptide), intravesical instillation, or intravenous infusion. FDA reviewers stated plainly that they found no studies administering BPC-157 to humans by the oral, subcutaneous, nasal, or transdermal routes, which happen to be the only routes sold to consumers today. In other words, the forms of BPC-157 people actually buy have zero published human safety or efficacy data behind them, in any condition.

What Evidence Would Be Needed to Establish Effectiveness

Closing that gap would require several things the current record lacks:

• Full peer-reviewed publication of the ulcerative colitis trial, with a defined primary endpoint, stated inclusion and exclusion criteria, and a pre-specified statistical analysis plan, not just a meeting abstract.
• An adequately powered, randomized, placebo-controlled trial, ideally replicated by an independent research group, since one small two-week study cannot establish efficacy for a chronic disease.
• Human pharmacokinetic and safety data specific to each route of administration actually sold to patients today (oral, subcutaneous, nasal, transdermal), since none currently exists.
• Clear characterization of the substance itself, including free base versus acetate form, purity, and stability, so quality standards can be set and individual batches can be verified against them.
• Follow-up long enough to matter for a relapsing, chronic condition like ulcerative colitis, rather than the two-week window used in the only existing human trial.

Until studies like that exist, “the FDA is reviewing BPC-157 for gut health” and “BPC-157 is proven to help gut health” remain two very different statements.

Bottom Line

BPC-157’s real origin story is gastric, not athletic. It was discovered in stomach research and tested for decades in animal models of ulcers, colitis, and intestinal healing before anyone marketed it for tendons. That history is why the FDA’s 2026 review zeroed in on ulcerative colitis rather than sports recovery, and why the agency drew a hard boundary around it: no submitted evidence meant no review for Crohn’s disease or celiac disease, and thin, non-peer-reviewed evidence meant a recommendation against inclusion even for the one indication regulators did examine.

An advisory committee vote to recommend BPC-157 for the compounding list is not the same as FDA approval, and it is not evidence that BPC-157 works for ulcerative colitis, Crohn’s disease, celiac disease, or “gut health” generally. It means regulators are debating how to manage a substance that is already circulating widely, using the one indication with any human data behind it as the test case.

For a broader look at BPC-157’s overall research status, safety profile, and current availability, see AlphaMD’s BPC-157 peptide page. For what the July 2026 advisory committee vote means for BPC-157 alongside TB-500, KPV, and MOTS-c, see AlphaMD’s breakdown of the FDA panel vote.